Gastrointestinal lymphomas in a North American population: clinicopathologic features from one major Central-Midwestern United States tertiary care medical center

Diagnostic Pathology

TuDung T Nguyen²  Anjum Hassan²  Friederike Kreisel²  John L Frater²  Julie Branson²  Diane Robirds²  Jingqin Luo¹  Joshua Warrick² 

[1] Department of Biostatistics, Washington University Medical School, St. Louis, MO, USA;Department of Pathology & Immunology, Washington University Medical School, 660 S. Euclid Ave, Campus Box 8118, St. Louis, MO 63110, USA

关键词: Locations;    Molecular features;    Secondary versus primary;    Gastrointestinal lymphoma;   

Others  :  808050
DOI  :  10.1186/1746-1596-7-76

 received in 2012-03-02, accepted in 2012-05-22,  发布年份 2012

【 摘 要 】

Background

Gastrointestinal (GI) lymphomas are very common types of extranodal lymphomas, and we hypothesize there are regional differences in subtype, distribution in the GI tract, and epidemiological features among the different populations.

Methods

We retrospectively evaluated the clinical, molecular and histologic features of North American primary and secondary GI lymphomas diagnosed from 2000–2009 seen at our institution. We utilized immunohistochemistry and fluorescence in situ hybridization to further evaluate a subset of the gastric lymphomas.

Results

Extranodal marginal zone lymphomas of mucosal associated lymphoid tissue (MALTs) and diffuse large B cell lymphomas (DLBCLs) were the most common subtypes of GI lymphomas. Select gastric DLBCLs (N = 6) and MALTs (N = 13) were further examined for API2-MALT1 and IGH translocations, and P16 and P53 protein expression. Gastric MALTs showed frequent API2-MALT1 (38%) but not IGH translocations (0%), and the DLBCLs showed neither translocation. Expression of P16 and P53 proteins and the proliferative index were compared between high grade gastric lymphomas (gastric DLBCLs) and low grade gastric lymphomas (gastric MALTs). P53 overexpression (P = 0.008) and a high proliferation index [Ki-67] (P = 0.00042) were significantly associated with gastric DLBCL, but no statistically significant difference was observed in P16 expression (p = 0.108) between gastric DLBCL and gastric MALT.

Conclusion

Our study revealed that GI lymphomas from a Central-Midwestern North American population showed differences and similarities to non-North American cohorts. In addition, API2-MALT1, P16 and P53 abnormalities occurred frequently in gastric lymphomas from this North American population.

Virtual slides

The virtual slides for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1415505838687793 webcite

【 授权许可】

   
2012 Warrick et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Crump M, Gospodarowicz M, Shepherd FA: Lymphoma of the gastrointestinal tract. Semin Oncol 1999, 26:324-337.
• [2]Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rube C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M: Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001, 19:3861-3873.
• [3]Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M: Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 2003, 97:2462-2473.
• [4]Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T: Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma 2006, 47:2140-2146.
• [5]Krugmann J, Dirnhofer S, Gschwendtner A, Berresheim U, Greil R, Krugmann K, Fend F: Primary gastrointestinal B-cell lymphoma. A clincopathological and immunohistochemical study of 61 cases with an evaluation of prognostic parameters. Pathol Res Pract 2001, 197:385-393.
• [6]Fischbach W, Dragosics B, Kolve-Goebeler ME, Ohmann C, Greiner A, Yang Q, Bohm S, Verreet P, Horstmann O, Busch M, Duhmke E, Muller-Hermelink HK, Wilms K, Allinger S, Bauer P, Bauer S, Bender A, Brandstatter G, Chott A, Dittrich C, Erhart K, Eysselt D, Ellersdorfer H, Ferlitsch A, Fridrik MA, Gartner A, Hausmaninger M, Hinterberger W, Hugel K, Ilsinger P, et al.: Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology 2000, 119:1191-1202.
• [7]Hansen PB, Vogt KC, Skov RL, Pedersen-Bjergaard U, Jacobsen M, Ralfkiaer E: Primary gastrointestinal non-Hodgkin's lymphoma in adults: a population-based clinical and histopathologic study. J Intern Med 1998, 244:71-78.
• [8]Halme L, Mecklin JP, Juhola M, Krees R, Palmu A: Primary gastrointestinal non- Hodgkin's lymphoma. A population based study in central Finland in 1975–1993. Acta Oncol 1997, 36:69-74.
• [9]Mihaljevic B, Nedeljkov-Jancic R, Vujicic V, Antic D, Jankovic S, Colovic N: Primary extranodal lymphomas of gastrointestinal localizations: a single institution 5-yr experience. Med Oncol 2006, 23:225-235.
• [10]Andrews CN, John Gill M, Urbanski SJ, Stewart D, Perini R, Beck P: Changing epidemiology and risk factors for gastrointestinal non-Hodgkin's lymphoma in a North American population: population-based study. Am J Gastroenterol 2008, 103:1762-1769.
• [11]Contreary K, Nance FC, Becker WF: Primary lymphoma of the gastrointestinal tract. Ann Surg 1980, 191:593-598.
• [12]Weingrad DN, Decosse JJ, Sherlock P, Straus D, Lieberman PH, Filippa DA: Primary gastrointestinal lymphoma: a 30-year review. Cancer 1982, 49:1258-1265.
• [13]Forman D, Pisani P: Gastric cancer in Japan–honing treatment, seeking causes. N Engl J Med 2008, 359:448-451.
• [14]Sagaert X, De Wolf-Peeters C, Noels H, Baens M: The pathogenesis of MALT lymphomas: where do we stand? Leukemia 2007, 21:389-396.
• [15]Sanchez-Beato M, Sanchez-Aguilera A, Piris MA: Cell cycle deregulation in B-cell lymphomas. Blood 2003, 101:1220-1235.
• [16]Takino H, Okabe M, Li C, Ohshima K, Yoshino T, Nakamura S, Ueda R, Eimoto T, Inagaki H: p16/INK4a gene methylation is a frequent finding in pulmonary MALT lymphomas at diagnosis. Mod Pathol 2005, 18:1187-1192.
• [17]Du MQ, Isaccson PG: Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002, 3:97-104.
• [18]Farinha P, Gascoyne RD: Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005, 23:6370-6378.
• [19]Dierlamm J, Stefanova M, Wlodarska I, Hinz K, Maes B, Michaux L, Stul M, Verhoef G, Thomas J, De Wolf-Peeters C, Van den Berghe H, Hossfeld DK, Hagemeijer A: Analysis of the P53, RB/D13S25, and P16 tumor suppressor genes in marginal zone B-cell lymphoma: An interphase fluorescence in situ hybridization study. Cancer Genet Cytogenet 2000, 120:1-5.
• [20]Martinez-Delgado B, Fernandez-Piqueras J, Garcia MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J: Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 1997, 11:425-428.
• [21]Park S, Kim KM, Kim JJ, Lee JH, Rhee JC, Ko YH: Methylation of p16INK4A and mitotic arrest defective protein 2 (MAD2) genes in gastric marginal-zone B-cell lymphomas. Acta Haematol 2008, 120:217-224.
• [22]Min KO, Seo EJ, Kwon HJ, Lee EJ, Kim WI, Kang CS, Kim KM: Methylation of p16(INK4A) and p57(KIP2) are involved in the development and progression of gastric MALT lymphomas. Mod Pathol 2006, 19:141-148.
• [23]Lewin KJ, Ranchod M, Dorfman RF: Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer 1978, 42:693-707.
• [24]Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
• [25]Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M, et al.: Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994, 5:397-400.
• [26]Ruskone-Fourmestraux A, Delmer A, Hennequin C: Gastro-intestinal lymphomas. Gastroenterol Clin Biol 2006, 30(2):2S81-2S90.
• [27]Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A: Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004, 63:314-322.
• [28]Andriani A, Zullo A, Di Raimondo F, Patti C, Tedeschi L, Recine U, Caruso L, Bonanno G, Chiarenza A, Lizzani G, Miedico A, Romanelli A, Costa A, Linea C, Marrone C, Mirto S, Mistretta A, Montalbano L, Restivo G, Vinci M, Bibas M, Hassan C, Stella F, Cottone M, Morini S: Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study. Aliment Pharmacol Ther 2006, 23:721-726.
• [29]Erkurt MA, Aydogdu I, Kuku I, Kaya E, Basaran Y: Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas: 10 years of experience from a single center in eastern Anatolia. Med Princ Pract 2009, 18:399-406.
• [30]Remstein ED, Dogan A, Einerson RR, Paternoster SF, Fink SR, Law M, Dewald GW, Kurtin PJ: The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006, 30:1546-1553.
• [31]Damaj G, Verkarre V, Delmer A, Solal-Celigny P, Yakoub-Agha I, Cellier C, Maurschhauser F, Bouabdallah R, Leblond V, Lefrere F, Bouscary D, Audouin J, Coiffier B, Varet B, Molina T, Brousse N, Hermine O: Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol 2003, 14:623-629.
• [32]Misdraji J, Harris NL, Hasserjian RP, Lauwers GY, Ferry JA: Primary follicular lymphoma of the gastrointestinal tract. Am J Surg Pathol 2011, 35:1255-1263.
• [33]Zullo A, Hassan C, Cristofari F, Perri F, Morini S: Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond. World J Gastrointest Oncol 2010, 2:181-186.
• [34]Cuttner J, Werther JL, McGlynn P, Chen A, Bodian C, Ogata S, Strauchen J, Troy K, Itzkowitz S: Seroprevalence of Helicobacter pylori infection in patients with lymphoma. Leuk Lymphoma 2001, 40:591-597.
• [35]Zullo A, Hassan C, Andriani A, Cristofari F, Cardinale V, Spinelli GP, Tomao S, Morini S: Primary low-grade and high-grade gastric MALT-lymphoma presentation. J Clin Gastroenterol 2010, 44:340-344.
• [36]Kondo T, Oka T, Sato H, Shinnou Y, Washio K, Takano M, Morito T, Takata K, Ohara N, Ouchida M, Shimizu K, Yoshino T: Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int J Oncol 2009, 35:547-557.
• [37]Neumeister P, Hoefler G, Beham-Schmid C, Schmidt H, Apfelbeck U, Schaider H, Linkesch W, Sill H: Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas. Gastroenterology 1997, 112:1871-1875.
• [38]Huang Q, Ai L, Zhang ZY, Fan CY, Weiss LM: Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China. Mod Pathol 2004, 17:416-422.
• [39]Yang Y, Wei ZJ, Zhai Y: The significance of p16 protein and Ki-67 antigen expression in gastric mucosa-associated lymphoid tissue lymphoma. Zhonghua Nei Ke Za Zhi 2008, 47:743-745.
• [40]Hall PA, Lane DP: p53 in tumour pathology: can we trust immunohistochemistry?-- Revisited! J Pathol 1994, 172:1-4.
• [41]Li HL, Sun BZ, Ma FC: Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa- associated lymphoid tissue lymphoma. World J Gastroenterol 2004, 10:1862-1866.
• [42]Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT: Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin Cancer Res 1999, 5:1085-1091.
• [43]Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y, Hamoudi RA, Diss TC, Dogan A, Megraud F, Rambaud JC, Du MQ, Isaacson PG: Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001, 357:39-40.
• [44]Starostik P, Patzner J, Greiner A, Schwarz S, Kalla J, Ott G, Muller-Hermelink HK: Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 2002, 99:3-9.
• [45]Schreuder MI, Hoeve MA, Hebeda KM, Verdijk MA, Ligtenberg MJ, Bot FJ, Chott A, van Krieken JH: Mutual exclusion of t(11;18)(q21;q21) and numerical chromosomal aberrations in the development of different types of primary gastric lymphomas. Br J Haematol 2003, 123:590-599.
• [46]Nakamura S, Ye H, Bacon CM, Goatly A, Liu H, Kerr L, Banham AH, Streubel B, Yao T, Tsuneyoshi M, Savio A, Takeshita M, Dartigues P, Ruskone-Fourmestraux A, Matsumoto T, Iida M, Du MQ: Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. Clin Cancer Res 2008, 14:3002-3010.
• [47]Huang X, Zhang Z, Liu H, Ye H, Chuang SS, Wang J, Lin S, Gao Z, Du MQ: t(11;18)(q21;q21) in gastric MALT lymphoma and diffuse large B-cell lymphoma of Chinese patients. Hematol J 2003, 4:342-345.
• [48]Barth TF, Bentz M, Leithauser F, Stilgenbauer S, Siebert R, Schlotter M, Schlenk RF, Dohner H, Moller P: Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes Cancer 2001, 31:316-325.
• [49]Wang G, Auerbach A, Wei M, Dow N, Barry TS, Hodge L, Schaffer D, Sobin LH, Aguilera NS: t(11;18)(q21;q21) in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in stomach: a study of 48 cases. Mod Pathol 2009, 22:79-86.